Suggestions
Idioma
Guide for authors
Searcher
Journal Information
Vol. 225. Issue 9.
(November 2025)
Cite
Cite
Share
Download PDF
More article options
Visits
2044
Vol. 225. Issue 9.
(November 2025)
ORIGINAL

Evolución de biomarcadores de angiogénesis e inflamación en pacientes con telangiectasia hemorrágica hereditaria durante el tratamiento con bevacizumab: protocolo de estudio

Evolution of angiogenic and inflammatory biomarkers in patients with hereditary hemorrhagic telangiectasia during treatment with bevacizumab: study protocol
Visits
2044
B. Villanuevaa,b,c, A. Figuerasc,d, R. Torres-Iglesiasa,b,c, M. Muñoza,e, S. Moreno-Lopesa,b,c, N. Trullén-Malareta,b,c, A. Martínezf, F. Viñalsc,d,g, A. Riera-Mestrea,b,c,g,h,
Corresponding author
ariera@bellvitgehospital.cat

Autor para correspondencia.
a Unidad de Telangiectasia Hemorrágica Hereditaria. Hospital Universitari de Bellvitge, Barcelona, España
b Servicio de Medicina Interna. Hospital Universitari de Bellvitge, Barcelona, España
c Instituto de investigación biomédica de Bellvitge (IDIBELL), Barcelona, España
d Laboratorio de Señalización Molecular, Programa de Mecanismos Moleculares y Terapia Experimental en Oncología (ONCOBELL), Instituto de Investigación Biomédica de Bellvitge (IDIBELL), Barcelona, España
e Servicio de Farmacia. Hospital Universitari de Bellvitge, Barcelona, España
f Grupo de Angiogénesis. Centro de Investigación Biomédica de La Rioja (CIBIR), Logroño, España
g Facultad de medicina y ciencias de la Salud. Universitat de Barcelona, Barcelona, España
h Centro de Investigación Biomédica en Red en Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, España
This item has received
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Resumen
Antecedentes

La telangiectasia hemorrágica hereditaria (HHT) es una enfermedad minoritaria caracterizada por la presencia de telangiectasias mucocutáneas y malformaciones vasculares (MVs) viscerales. El tratamiento con bevacizumab ha demostrado buenos resultados en los pacientes con insuficiencia cardiaca con gasto cardiaco elevado (ICGCE) por afectación hepática o en la afectación gastrointestinal (GI) grave. Sin embargo, no existe evidencia sobre cómo monitorizar dicho tratamiento mediante el uso de biomarcadores.

Material y métodos

Se trata de un estudio exploratorio, observacional, prospectivo y unicéntrico realizado en una unidad de referencia de HHT. El periodo de inclusión para el inicio de bevacizumab fue de enero de 2022 a mayo de 2023. Se seleccionaron los pacientes con indicación para iniciar bevacizumab y se les practicaron analíticas de sangre basal y durante la fase de inducción (36 semanas) y mantenimiento con el fin de analizar 21 biomarcadores relacionados con angiogénesis e inflamación. Además, se seleccionaron pacientes controles con HHT sin indicación de bevacizumab y controles sanos emparejados 1:1:1 por edad y sexo (y subtipo genético en los pacientes HHT), a los que se les realizó un estudio basal de estos biomarcadores. El objetivo principal es analizar la evolución de dichos biomarcadores en los pacientes con HHT tratados con bevacizumab. Como objetivos secundarios se analizarán diferencias basales en la determinación de estos biomarcadores entre los tres grupos y se correlacionarán las concentraciones con las de hemoglobina como parámetro de gravedad de la enfermedad.

Descripción de los grupos

Durante el periodo de estudio se incluyeron nueve pacientes con indicación de bevacizumab, siete por anemia de origen GI y dos por afectación hepática con ICGCE, con una edad media global de 70 años±8,4 años, y posteriormente se seleccionaron los respectivos nueve pacientes con HHT sin bevacizumab y nueve controles sin HHT.

Conclusiones

Los resultados de este estudio exploratorio aportarán nuevo conocimiento respecto a potenciales biomarcadores para la monitorización de la respuesta al tratamiento con bevacizumab. Además, podría generar nuevas hipótesis para estudiar el papel de determinados biomarcadores, tanto a nivel fisiopatológico, diagnóstico como terapéutico.

Palabras clave:
Biomarcadores
Angiogénesis
Inflamación
Bevacizumab
Telangiectasia hemorrágica hereditaria
Abstract
Background

Hereditary hemorrhagic telangiectasia (HHT) is a rare disease characterized by mucocutaneous telangiectasia and visceral vascular malformations. Treatment with bevacizumab is recommended in patients with liver involvement and high output cardiac failure (HOCF) or those with severe gastrointestinal (GI) involvement. However, there is no evidence on how to monitor such treatment using biomarkers.

Material and methods

This is an exploratory, observational, prospective, single-center study carried out in an HHT referral unit. The inclusion period for the start of bevacizumab was from January 2022 to May 2023. Patients with an indication for starting bevacizumab were selected and underwent blood tests at baseline and during the induction (36 weeks) and maintenance phase in order to analyze 21 biomarkers related to angiogenesis and inflammation. In addition, control HHT patients without indication for bevacizumab and healthy controls matched 1:1:1 by age, sex, and genetic subtype (for HHT patients) underwent a baseline biomarker study. The main objective is to analyze the evolution of these biomarkers in patients with HHT treated with bevacizumab. As secondary objectives, baseline differences in the concentration of these biomarkers between the three groups and correlation with the hemoglobin levels will be analyzed.

Groups description

During the study period, nine patients with an indication for bevacizumab were included, seven due to anemia of GI origin and two due to liver involvement with HOCF, with an overall mean age of 70±8.4 years, and subsequently the respective nine patients with HHT without bevacizumab and nine controls without HHT were selected.

Conclusions

The results of this exploratory study will provide new knowledge regarding potential biomarkers for monitoring the response to treatment with bevacizumab. Furthermore, it could generate new hypotheses about the role of certain biomarkers at the pathophysiological, diagnostic, and therapeutic levels.

Keywords:
Biomarkers
Angiogenesis
Inflammation
Bevacizumab
Hereditary hemorrhagic telangiectasia

Article

These are the options to access the full texts of the publication Revista Clínica Española (English Edition)
Member
Si es usted socio de FESEMI siga los siguientes pasos:

Diríjase desde aquí a la web de la >>>https://www.fesemi.org/publicaciones/revista-clinica/noticias<<< e inicie sesión mediante el formulario que se encuentra en la barra superior, pulsando sobre el candado.

Deslice el cursor hacia abajo hasta la sección "PUBLICACIONES" y pinche en "Revista Clínica Española":

>>>https://www.fesemi.org/publicaciones/revista-clinica/noticias<<<

Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to
Revista Clínica Española (English Edition)
Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
Email
Bibiliografía
[1]
The portal for rare diseases and orphan drugs. [consultado 22 Jul 2024]. Disponible en: https://www.orpha.net
[2]
C.L. Shovlin.
Hereditary haemorrhagic telangiectasia: pathophysiology, diagnosis and treatment.
Blood Rev, 24 (2010), pp. 203-219
[3]
A. Riera-Mestre, J. Ribas, J. Castellote.
Medical management of hemorrhagic hereditary telangiectasia in adult patients.
Med Clínica., 152 (2019), pp. 274-280
[4]
M.E. Faughnan, J.J. Mager, S.W. Hetts, V.A. Palda, K. Lang-Robertson, E. Buscarini, et al.
Second International Guidelines for the Diagnosis and Management of Hereditary Hemorrhagic Telangiectasia.
Ann Intern Med., 173 (2020), pp. 989-1001
[5]
C.L. Shovlin, A.E. Guttmacher, E. Buscarini, M.E. Faughnan, R.H. Hyland, C.J. Westermann, et al.
Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome).
[6]
R. Sánchez-Martínez, A. Iriarte, J.M. Mora-Luján, J.L. Patier, D. López-Wolf, A. Ojeda, et al.
Current HHT genetic overview in Spain and its phenotypic correlation: data from RiHHTa registry.
Orphanet J Rare Dis., 15 (2020), pp. 138
[7]
J. McDonald, W. Wooderchak-Donahue, C. VanSant Webb, K. Whitehead, D.A. Stevenson, P. Bayrak-Toydemir.
Hereditary hemorrhagic telangiectasia: Genetics and molecular diagnostics in a new era.
Front Genet., 5 (2015), pp. 1-9
[8]
F. Medina-Jover, A. Riera-Mestre, F. Viñals.
Rethinking growth factors: the case of BMP9 during vessel maturation.
Vasc Biol., 4 (2022), pp. R1-R14
[9]
S.K. Meurer, R. Weiskirchen.
Endoglin: An ‘Accessory’ Receptor Regulating Blood Cell Development and Inflammation.
Int J Mol Sci., 21 (2020), pp. 9247
[10]
T. Al Tabosh, M. Al Tarrass, L. Tourvieilhe, A. Guilhem, S. Dupuis-Girod, S. Bailly.
Hereditary hemorrhagic telangiectasia: from signaling insights to therapeutic advances.
J Clin Invest., 134 (2024),
[11]
S.K. Khalid, G. Garcia-Tsao.
Hepatic Vascular Malformations in Hereditary Hemorrhagic Telangiectasia.
Semin. Liver Dis., 28 (2008), pp. 247-258
[12]
C. Vázquez, M.L. Gonzalez, A. Ferraris, J.C. Bandi, M.M. Serra.
Bevacizumab for treating Hereditary Hemorrhagic Telangiectasia patients with severe hepatic involvement or refractory anemia.
PLoS One., 15 (2020),
[13]
A. Chavan, S. Schumann-Binarsch, B. Schmuck, F. Oltmer, U. Geisthoff, F. Hoppe, et al.
Emerging role of bevacizumab in management of patients with symptomatic hepatic involvement in Hereditary Hemorrhagic Telangiectasia.
Am J Hematol., 92 (2017), pp. E641-E644
[14]
S. Dupuis-Girod, I. Ginon, J.C. Saurin, D. Marion, E. Guillot, E. Decullier, et al.
Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output.
JAMA., 307 (2012), pp. 948-955
[15]
A. Riera-Mestre, J.M. Mora Luján, R. Sanchez Martínez, M.A. Torralba Cabeza, J.L. Patier de la Peña, M.C. Juyol Rodrigo, et al.
Computerized registry of patients with hemorrhagic hereditary telangiectasia (RiHHTa registry) in Spain: objectives, methods, and preliminary results.
Rev Clin Esp (Barc)., 218 (2018), pp. 468-476
[16]
C. Canzonieri, L. Centenara, F. Ornati, F. Pagella, E. Matti, C. Alvisi, et al.
Endoscopic evaluation of gastrointestinal tract in patients with hereditary hemorrhagic telangiectasia and correlation with their genotypes.
Genet Med., 16 (2014), pp. 3-10
[17]
J.M. Mora-Luján, A. Iriarte, E. Alba, Sánchez-Corral MÁ, A. Berrozpe, P. Cerdà, et al.
Gastrointestinal bleeding in patients with hereditary hemorrhagic telangiectasia: risk factors and endoscopic findings.
J Clin Med., 9 (2019), pp. 82
[18]
A.V. Longacre, C.P. Gross, M. Gallitelli, K.J. Henderson, R.I. White Jr., D.D. Proctor.
Diagnosis and management of gastrointestinal bleeding in patients with hereditary hemorrhagic telangiectasia.
Am J Gastroenterol., 98 (2003), pp. 59-65
[19]
R. Torres-Iglesias, J.M. Mora-Luján, A. Iriarte, P. Cerdà, E. Alba, M.Á. Sánchez-Corral, et al.
Long-term use of somatostatin analogs for chronic gastrointestinal bleeding in hereditary hemorrhagic telangiectasia.
Front Med (Lausanne)., 12 (2023),
[20]
H. Al-Samkari, R.S. Kasthuri, J.G. Parambil, H.A. Albitar, Y.A. Almodallal, C. Vázquez, et al.
An international, multicenter study of intravenous bevacizumab for bleeding in hereditary hemorrhagic telangiectasia: the InHIBIT-Bleed study.
Haematologica., 106 (2021), pp. 2161-2169
[21]
R.S. Vasan.
Biomarkers of cardiovascular disease: molecular basis and practical considerations.
Circulation., 113 (2006), pp. 2335-2362
[22]
A. Riera-Mestre, P. Cerda, A. Iriarte, Graupera, M. Viñals.
Translational medicine in hereditary hemorrhagic telangiectasia.
Eur J Intern Med., 95 (2022), pp. 32-37
[23]
B. Villanueva, P. Cerdà, R. Torres-Iglesias, J.L. Rocamora, A. Figueras, F. Viñals, et al.
Potential angiogenic biomarkers in hereditary hemorrhagic telangiectasia and other vascular diseases.
Eur J Intern Med., 115 (2023), pp. 10-17
[24]
A. Iriarte, L. Ochoa-Callejero, J. García-Sanmartín, P. Cerdà, P. Garrido, J. Narro-Íñiguez, et al.
Adrenomedullin as a potential biomarker involved in patients with hereditary hemorrhagic telangiectasia.
Eur J Intern Med., 88 (2021), pp. 89-95
[25]
F. Robert, A. Desroches-Castan, S. Bailly, S. Dupuis-Girod, J.J. Feige.
Future treatments for hereditary hemorrhagic telangiectasia.
Orphanet J Rare Dis., 15 (2020), pp. 4
[26]
A. Cirulli, A. Liso, F. D’Ovidio, A. Mestice, G. Pasculli, M. Gallitelli, et al.
Vascular endothelial growth factor serum levels are elevated in patients with hereditary hemorrhagic telangiectasia.
Acta Haematol., 110 (2003), pp. 29-32
[27]
J. Steineger, T. Ueland, P. Aukrust, A. Michelsen, T. Osnes, K. Heimdal, et al.
Pentraxin 3 level is elevated in hereditary hemorrhagic telangiectasia and reflects the severity of disease-associated epistaxis.
Laryngoscope., 129 (2019), pp. E44-E49
[28]
S.E. Wetzel-Strong, S. Weinsheimer, J. Nelson, L. Pawlikowska, D. Clark, M.D. Starr, et al.
Pilot investigation of circulating angiogenic and inflammatory biomarkers associated with vascular malformations.
Orphanet J Rare Dis., 16 (2021), pp. 372
[29]
M.E. Faughnan, V.A. Palda, G. Garcia-Tsao, U.W. Geisthoff, J. McDonald, D.D. Proctor, et al.
International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia.
J Med Genet., 48 (2011), pp. 73-87
[30]
J.B. Hoag, P. Terry, S. Mitchell, D. Reh, C.A. Merlo.
An epistaxis severity score for hereditary hemorrhagic telangiectasia.
Laryngoscope., 120 (2010), pp. 838-843
[31]
B. Villanueva, A. Cañabate, R. Torres-Iglesias, P. Cerdà, E. Gamundí, Q. Ordi, et al.
Minimal encephalopathy in hereditary hemorrhagic telangiectasia patients with portosystemic vascular malformations.
Orphanet J Rare Dis., 19 (2024), pp. 484
[32]
B. Villanueva, MÁ Sánchez-Corral, E. Alba, Q. Ordi, Y. Ruiz, R. Torres-Iglesias, et al.
Long-term follow-up of hereditary hemorrhagic telangiectasia patients without significant pulmonary right-to-left shunt at screening.
Eur J Intern Med., 132 (2024), pp. 106-112
[33]
A. Riera-Mestre, P. Cerdà, Y.C. Guzmán, A. Iriarte, A. Torroella, J.M. Mora-Luján, et al.
Perioperative Complications and Long-Term Follow-Up of Liver Transplantation in Hemorrhagic Hereditary Telangiectasia: Report of Three Cases and Systematic Review.
J Clin Med., 11 (2022), pp. 5624
[34]
R. Torres-Iglesias, J.M. Mora-Luján, A. Iriarte, P. Cerdà, E. Alba, M.Á. Sánchez-Corral, et al.
Long-term use of somatostatin analogs for chronic gastrointestinal bleeding in hereditary hemorrhagic telangiectasia.
Front Med (Lausanne)., 10 (2023),
[35]
J. Herbers, R. Miller, A. Walther, L. Schindler, K. Schmidt, W. Gao, et al.
How to deal with non-detectable and outlying values in biomarker research: Best practices and recommendations for univariate imputation approaches.
Compr Psychoneuroendocrinol., 7 (2021),
[36]
H. Sadick, F. Riedel, R. Naim, U. Goessler, K. Hörmann, M. Hafner, et al.
Patients with hereditary hemorrhagic telangiectasia have increased plasma levels of vascular endothelial growth factor and transforming growth factor-beta1 as well as high ALK1 tissue expression.
Haematologica., 90 (2005), pp. 818-828
[37]
H. Sadick, J. Hage, U. Goessler, G. Bran, F. Riedel, P. Bugert, et al.
Does the genotype of HHT patients with mutations of the ENG and ACVRL1 gene correlate to different expression levels of the angiogenic factor VEGF?.
Int J Mol Med., 22 (2008), pp. 575-580
[38]
L. Ojeda-Fernandez, L. Barrios, A. Rodriguez-Barbero, L. Recio-Poveda, C. Bernabeu, L.M. Botella.
Reduced plasma levels of Ang-2 and sEng as novel biomarkers in hereditary hemorrhagic telangiectasia (HHT).
Clin Chim Acta., 411 (2010), pp. 494-499
Idiomas
Revista Clínica Española (English Edition)
Article options
Tools